SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-20-018916
Filing Date
2020-10-05
Accepted
2020-10-05 16:05:25
Documents
8
Period of Report
2020-09-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm 8-K 57756
2 ex3-1.htm EX-3.1 15134
3 ex99-1.htm EX-99.1 47854
4 ex99-2.htm EX-99.2 50819
5 ex99-3.htm EX-99.3 50312
6 ex99-4.htm EX-99.4 48568
7 ex99-5.htm EX-99.5 47860
8 ex99-6.htm EX-99.6 26044
  Complete submission text file 0001493152-20-018916.txt   346066
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 201223580
SIC: 2834 Pharmaceutical Preparations